1.Howlader N，Noone A，Krapcho M，et al.SEER cancer statistics review，1975—2009（Vintage 2009 populations）.Bethesda，MD：National Cancer Institute；2012.

2.Shimada H，Ambros IM，Dehner LP，et al.Terminology and morphologic criteria of neuroblastic tumors.Recommendations by the International Neuroblastoma Pathology Committee.Cancer，1999（86）：349-363

3.Brodeur G M，Pritchard J，Berthold F，et al.Revisions of the international criteria for neuroblastoma diagnosis，staging and response to treatment［J］.Prog Clin Biol Res，1994，385（11）：363-369.

4.Brodeur G M，Schneider S S，Hiemstra J L，et al.Cloning and analysis of a 1.2 mb N-myc amplicon from a human neuroblastoma［J］.Cancer Genetics & Cytogenetics，1993，66（2）：145.

5.李爱敏，张锦华，王弘，等.神经母细胞瘤骨髓转移细胞体外原代培养技术的实验研究［J］.中华小儿外科杂志，2004，25（3）：270-273.

6.王亚柱，王卫东.神经母细胞瘤髓内转移骨髓动力学变化规律的探讨［J］.中国医科大学学报，1998（2）：149-151.

7.Nakagawara A，Brodeur G M.Role of neurotrophins and their receptors in human neuroblastomas：a primary culture study［J］.European Journal of Cancer，1997，33（12）：2050-2053.

8.Hishiki T，Nimura Y，Isogai E，et al.Glial cell line-derived neurotrophic factor/neurturininduced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-Ret，GFR alpha-1，and GFR alpha-2.［J］.Cancer Research，1998，58（10）：2158.

9.Norris MD，Madafiglio J，Gilbert J，et al.Reversal of multidrug resistance-associated proteinmediated drug resistance in cultured human neuroblastoma cells by the quinolone antibiotic difloxacin.Med Pediatr Oncol，2001，36（1）：177-80.

10.Klement G，Baruchel S，Rak J，et al.Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.Journal of Clinical Investigation，2000，105（8）：15-24.

11.Kushner B H，Kramer K，Laquaglia M P，et al.Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma［J］.Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology，2004，22（24）：4888.

12.Baker D L，Schmidt M L，Cohn S L，et al.Outcome after reduced chemotherapy for intermediate-risk neuroblastoma［J］.New England Journal of Medicine，2010，363（14）：1313.

13.Emmenegger U，Shaked Y，Man S，et al.Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice.Molecular Cancer Therapeutics 2007，6（8）：2280.

14.Moroz V，Machin D，Faldum A，et al.Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma：a report from the International Neuroblastoma Risk Group Project.［J］.European Journal of Cancer，2011，47（4）：561-71.

15.Look A T，Hayes F A，Shuster J J，et al.Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma：a Pediatric Oncology Group study［J］.Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology，1991，9（4）：581-91.

16.Parodi F，Passoni L，Massimo L，et al.Identification of novel prognostic markers in relapsing localized resectable neuroblastoma.［J］.Omics A Journal of Integrative Biology，2011，15（15）：113-121.

17.Attiyeh E F，London W B，Mossé Y P，et al.Chromosome 1p and 11q deletions and outcome in neuroblastoma.［J］.New England Journal of Medicine，2005，353（21）：2243-53.

18.Ladenstein R，Ambros IM，Potschger U，et al.Prognostic significance of DNA di-tetraploidy in neuroblastoma.Med Pediatr Oncol，2001，36（1）：83-92.

19.Norris MD，Bordow SB，Marshall GM，et al.Expression of the gene for multidrug-resistanceassociated protein and outcome in patients with neuroblastoma.N Engl J Med，1996，334（4）：231-8.

20.Brodeur GM，Azar C，Brother M，et al.Neuroblastoma.Effect of genetic factors on prognosis and treatment.Cancer，1992，70（6 Suppl）：1685-94.

21.唐锁勤，黄东生，王建文，等.大剂量化疗造血干细胞移植治疗IV期神经母细胞瘤的长期疗效研究［J］.中国当代儿科杂志，2006，8（2）：93-96.

22.陈苏宁，于飞，蔡炜嵩，等.中西医结合治疗晚期神经母细胞瘤44例报道［J］.中国小儿血液与肿瘤杂志，2008，13（4）：178-180.

23.张谊，张伟令，黄东生，等.4期神经母细胞瘤伴有骨髓转移的化疗疗效分析及预后.2017全国小儿血液与肿瘤学术会议论文汇编，202